Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that gets inputs from
the amino acids, nutrients, growth factor, and environmental cues to regulate varieties of …

Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the
gold standard options for treating prostate cancer (PCa). These are initially effective, as …

In my PNAS Inaugural Article, I describe the development of the mTOR field, starting with
efforts to understand the mechanism of action of the drug rapamycin, which∼ 25 y ago led to …

Although the transition metal copper (Cu) is an essential nutrient that is conventionally
viewed as a static cofactor within enzyme active sites, a non-traditional role for Cu as a …

Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and
tumour suppressors affect the translation machinery, making aberrant translation a …

Metabolism research is undergoing a renaissance because many diseases are increasingly
recognized as being characterized by perturbations in intracellular metabolic regulation …

Mammalian target of rapamycin (mTOR) is a highly conserved Serine/Threonine (Ser/Thr)
protein kinase, which belongs to phosphatidylinositol-3-kinase-related kinase (PIKK) protein …

The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a
variety of environmental cues to regulate organismal growth and homeostasis. The pathway …

The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein
kinase, controls cell growth in response to nutrients and growth factors and is frequently …

The high rate of clinical response to protein-kinase-targeting drugs matched to cancer
patients with specific genomic alterations has prompted efforts to use cancer cell line (CCL) …